SAMANTHA DAVIS: Open Payments
NPI 1346361599 · FORT COLLINS, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$832 in 41 payments from 16 companies in 2025. Trend: 2023 $1,212 · 2024 $1,016 · 2025 $832
Food & beverage: $832
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 8 | $167 |
| Lilly USA, LLC | 5 | $91 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $83 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $75 |
| Otsuka America Pharmaceutical, Inc. | 3 | $61 |
| GlaxoSmithKline, LLC. | 3 | $60 |
| Antares Pharma, Inc. | 2 | $50 |
| Viatris Specialty LLC | 2 | $47 |
| Novo Nordisk Inc | 2 | $46 |
| AstraZeneca Pharmaceuticals LP | 2 | $35 |
Products named: VRAYLAR, CAPLYTA, Kerendia, REXULTI, MOUNJARO, XYOSTED, YUPELRI, ZEPBOUND.
Industry payments across CO — which companies pay providers there.
